<DOC>
	<DOCNO>NCT00940589</DOCNO>
	<brief_summary>The aim exploratory randomize , placebo control study evaluate efficacy Circadin速 2mg patient mild moderate Alzheimer Disease ( AD ) treat acetylcholinesterase ( AChE ) inhibitor . The effect add-on Circadin速 2mg vs. placebo decline cognitive skill global functioning , well daytime somnolence assess .</brief_summary>
	<brief_title>Efficacy Circadin速 2 mg Patients With Mild Moderate Alzheimer Disease Treated With AChE Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>1 . Written inform consent dictate local legal circumstance . 2 . Age range : adult patient 5085 year age . 3 . Gender : men woman . Women child bear potential within two year menopause must negative urine pregnancy test Screening Visit . 4 . A documented history confirm Alzheimer 's disease 5 . Dementia severity : MMSE score &gt; 15 , 6 . Stable AChE inhibitor dose 2 month prior Screening visit . 7 . Stable medication nonexcluded concurrent medical condition four week prior screen visit . 8 . Stable dos B12 and/or Folic acid supplement least 3 month prior enrollment throughout study . 9 . Cranial image : evidence focal disease account dementia ( establish CT , PET MRI ) . If available scan ( CT , PET MRI ) , one must perform prior enrollment . 10 . Health : Physically acceptable study pathology likely occur immediately study , confirm medical history exam ECG . 11 . Clinical laboratory value must within normal limit , judge clinically significant investigator . 12 . Residence : Stable home situation plan move 28week investigational period . 13 . A family member regular caregiver available visit ensure compliance . The caregiver must speak fluent Hebrew , Russian English . 14 . Ability ingest oral medication participate schedule evaluation . 15 . Ability spend 2 daily hour outdoors expose sunlight . 1 . Severe agitation . 2 . Unstable medical condition , mental retardation . 3. moderate severe depression define DSMIV 4 . Use benzodiazepine hypnotic study precede four week . 5 . Use Circadin速 two week prior study enrollment . 6 . Pharmacological immunosuppression . 7 . Participation clinical trial investigational agent within two month prior study enrollment . 8 . Alcoholism . 9 . Known suspected hypersensitivity exogenous melatonin melatonin receptor agonist . 10 . Patients rare hereditary problem galactose intolerance , LAPP lactose deficiency glucose mal absorption . 11 . Renal Failure creatinine &gt; 150 micromol/l . 12 . Hepatic Failure ASAT ; ALAT ; GGT level three time upper normal limit . 13 . Clinically significant abnormal laboratory finding approve Safety Officer ( sponsor ) 14 . Other serious disease could interfere patient assessment . 15 . Caregivers unwilling unable give inform consent otherwise fulfill requirement study . 16 . Untreated B12 and/or Folic acid deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Acetylcholinesterase inhibitor</keyword>
	<keyword>cognitive function</keyword>
	<keyword>Circadin</keyword>
	<keyword>Sleep disturbance</keyword>
</DOC>